[Federal Register Volume 64, Number 200 (Monday, October 18, 1999)]
[Notices]
[Pages 56226-56227]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-27102]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importation of Controlled Substances, Notice of Application

    Pursuant to Section 1008 of the Controlled Substances Import and 
Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance is Schedule I or II and prior to issuing a 
regulation under Section 1002(a) authorizing the importation of such a 
substance, provide manufacturers holding registrations for the bulk 
manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with Section 1301.34 of Title 21, Code of 
Federal Regulations (CFR), notice is hereby given that on August 25, 
1999, Glaxo Wellcome Inc., Attn: Jeffrey A. Weiss, 1011 North Arendell 
Avenue, P.O. Box 1271, Zebulon, North Carolina 27597-2309, made 
application by renewal to the Drug Enforcement Administration to be 
registered as an importer of remifentanil (9739), a basic class of 
controlled substance listed in Schedule II.
    The remifentanil is being imported for the production of Ultiva 
dosage forms and for research and new product development.
    Any manufacturer holding, or applying for, registration as a bulk 
manufacturer of this basic class of controlled substance may file 
written comments on or objections to the

[[Page 56227]]

application described above and may, at the same time, file a written 
request for a hearing on such application in accordance with 21 CFR 
1301.43 in such form as prescribed by 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed, in quintuplicate, to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration, United 
States Department of Justice, Washington, D.C. 20537, Attention: DEA 
Federal Register Representative (CCR), and must be filed no later than 
November 17, 1999.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e), and (f). As noted in a previous notice at 40 FR 43745-46 
(September 23, 1975), all applicants for registration to import basic 
class of any controlled substance in Schedule I or II are and will 
continue to be required to demonstrate to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration that the requirements for such registration pursuant to 
21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42(a), (b), (c), 
(d), (e), and (f) are satisfied.

    Dated: October 8, 1999.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 99-27102 Filed 10-15-99; 8:45 am]
BILLING CODE 4410-09-M